United Therapeutics (NASDAQ:UTHR) Hits New 1-Year High – Time to Buy?

by · The Markets Daily

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report)’s share price hit a new 52-week high on Friday . The company traded as high as $494.74 and last traded at $495.1590, with a volume of 203836 shares. The stock had previously closed at $488.51.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. UBS Group raised their price target on United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. HC Wainwright raised their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Wells Fargo & Company upped their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research report on Wednesday, October 29th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a report on Wednesday, November 19th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $505.00.

View Our Latest Stock Report on United Therapeutics

United Therapeutics Stock Up 1.2%

The business has a 50-day simple moving average of $456.99 and a two-hundred day simple moving average of $372.72. The stock has a market capitalization of $21.28 billion, a price-to-earnings ratio of 18.73, a P/E/G ratio of 4.81 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. During the same quarter in the previous year, the business earned $6.39 EPS. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. On average, analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $416.35, for a total value of $9,367,875.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 619,487 shares of company stock worth $277,804,954. Company insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Chung Wu Investment Group LLC purchased a new stake in shares of United Therapeutics during the second quarter valued at $29,000. WealthCollab LLC raised its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares in the last quarter. SVB Wealth LLC acquired a new position in shares of United Therapeutics in the first quarter worth about $32,000. Finally, Wilmington Savings Fund Society FSB increased its position in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Further Reading